Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pharyngitis01:30

Acute Pharyngitis

4.1K
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
4.1K
Infection01:20

Infection

12.0K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
12.0K
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

1.2K
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
1.2K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

936
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
936
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.1K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

487
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
487

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Intersection of Human Rights, HIV and Sex Work: Implications for Ending AIDS in Thailand by 2030.

Journal of the International AIDS Society·2026
Same author

Barriers and Enabling Factors for Taking PrEP: The Lived Perspectives of Female, Male and Transgender Sex Workers in Thailand.

AIDS and behavior·2026
Same author

Rapid and profound decay of inducible and intact HIV genomes in early-treated Thai children.

The Journal of clinical investigation·2026
Same author

Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.

Human vaccines & immunotherapeutics·2026
Same author

Factors associated with PrEP use among sex workers: a cross-sectional study from female, male, and transgender sex workers in seven Thailand provinces.

Sexual health·2026
Same author

Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01<sub>E-4</sub> in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial.

The lancet. HIV·2025

Related Experiment Video

Updated: Jan 26, 2026

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

9.1K

Lessons from acute HIV infection.

Merlin L Robb1, Jintanat Ananworanich

  • 1aU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver SpringbHenry M. Jackson Foundation for The Advancement of Military Medicine, Bethesda, Maryland, USA.

Current Opinion in HIV and AIDS
|October 8, 2016
PubMed
Summary
This summary is machine-generated.

Understanding acute HIV infection (AHI) transmission is key for developing effective vaccines. Early treatment in AHI leads to smaller viral reservoirs, making individuals ideal candidates for therapeutic vaccines aimed at HIV remission.

More Related Videos

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

10.6K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.1K

Related Experiment Videos

Last Updated: Jan 26, 2026

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

9.1K
Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

10.6K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.1K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Acute HIV infection (AHI) is a critical window influencing long-term viral set point and disease progression.
  • Peak viremia during AHI predicts viral set point, with robust CD8 T-cell responses associated with lower set points.
  • Phylogenetic analyses reveal bottleneck selections and genetic signatures optimizing HIV transmission and variant fitness.

Purpose of the Study:

  • To understand transmission characteristics during acute HIV infection (AHI) for vaccine development.
  • To identify optimal candidates for therapeutic HIV vaccines aiming for remission.
  • To inform the design of preventive and therapeutic HIV vaccines based on AHI knowledge.

Main Methods:

  • Review of recent findings on HIV transmission during AHI.
  • Analysis of phylogenetic data of founder viruses.
  • Evaluation of the impact of antiretroviral treatment initiated during AHI.

Main Results:

  • Early antiretroviral treatment in AHI leads to smaller HIV reservoir size, improved CD4 T-cell recovery, and reduced viral escape.
  • Peak viremia during AHI predicts viral set point, influenced by HIV-specific CD8 T-cell responses.
  • HIV clades, transmission routes, and minor variants can impact vaccine efficacy.

Conclusions:

  • Knowledge of AHI informs the development of broadly protective preventive vaccines and host-viremia controlling therapeutic vaccines.
  • Therapeutic HIV vaccines for remission should target early-treated individuals with preserved immune systems and minimal viral escape.
  • Optimizing vaccine strategies requires understanding transmission dynamics and host immune responses during the acute phase of HIV infection.